Published in Drug Metab Dispos on September 23, 1983
Stereoselective propranolol metabolism in two drug induced rat hepatic microsomes. World J Gastroenterol (2000) 0.85
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82
Beta-adrenergic receptors support attention to extinction learning that occurs in the absence, but not the presence, of a context change. Front Behav Neurosci (2015) 0.77
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther (1986) 1.31
Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol (1999) 1.25
GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci (1974) 1.22
Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol (2001) 1.21
Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol (1998) 1.18
Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther (1972) 1.17
Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther (2000) 1.14
Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos (1996) 1.11
Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol (1998) 1.10
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res (2001) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos (1998) 1.02
Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther (2000) 1.01
Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther (1983) 1.01
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res (2001) 1.00
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol (1993) 1.00
Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica (2006) 0.99
Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol (2002) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 0.97
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. J Pharm Pharmacol (1999) 0.95
Acetylation of spermidine and spermine by rat liver and kidney chromatin. Arch Biochem Biophys (1977) 0.95
Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases. Xenobiotica (1997) 0.94
Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr (2000) 0.93
Taxol metabolism and disposition in cancer patients. Drug Metab Dispos (1995) 0.93
Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol (1993) 0.93
Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res (2000) 0.93
Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol (1983) 0.92
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade. J Pharmacol Exp Ther (1983) 0.92
Identification of the unusual polyamines 3,3'-diaminodipropylamine and N,N'-bis(3-aminoproply)-1,3-propanediamine in the white shrimp Penaeus setiferus. Biochem Biophys Res Commun (1977) 0.91
Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol (2000) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol (2005) 0.89
Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol (1996) 0.89
Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol (1995) 0.88
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther (1985) 0.88
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos (2000) 0.88
Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. J Pharmacol Exp Ther (1982) 0.88
Hep G2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica (1992) 0.87
Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res Commun Mol Pathol Pharmacol (1999) 0.87
Carbon dioxide is the major metabolite of quercetin in humans. J Nutr (2001) 0.87
Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. Res Commun Chem Pathol Pharmacol (1979) 0.87
Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam. Anesth Analg (1995) 0.86
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (1998) 0.86
Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. J Pharmacol Exp Ther (1983) 0.86
Isopropylamine, a biologically active deamination product of propranolol in dogs: identification of deuterated and unlabeled isopropylamine by gas chromatography-mass spectrometry. J Pharmacol Exp Ther (1972) 0.85
Isolation from urine of 4'-hydroxypropranolol sulfate, a major new propranolol metabolite, by ion-pair extraction. J Chromatogr (1984) 0.85
Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther (1979) 0.84
Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography. J Chromatogr (1975) 0.84
Propranolol effects on membrane repolarization time in isolated canine Purkinje fibers: threshold tissue content and the influence of exposure time. J Pharmacol Exp Ther (1980) 0.84
Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. J Cardiothorac Vasc Anesth (1993) 0.84
Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol (1986) 0.84
New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos (1982) 0.84
Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother Pharmacol (1995) 0.83
Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos (1998) 0.83
Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects. J Pharmacol Exp Ther (1977) 0.83
Identification of major sulfate conjugates in the metabolism of propranolol in dog and man. Drug Metab Dispos (1983) 0.83
Adrenergic nerve stimulation-induced release of propranolol from the perfused hindlimb and spleen of the dog and associated changes in postjunctional response. J Pharmacol Exp Ther (1983) 0.83
Combined effects of propranolol and ethanol on human psychomotor performance. Toxicol Appl Pharmacol (1983) 0.83
Pharmacokinetic model-driven infusion of fentanyl: assessment of accuracy. Anesthesiology (1990) 0.83